



# Tumescenamamide C, a cyclic lipodepsipeptide from *Streptomyces* sp. KUSC\_F05, exerts antimicrobial activity against the scab-forming actinomycete *Streptomyces scabiei*

Kensuke Kaneko<sup>1,2</sup> · Marika Mieda<sup>1</sup> · Yulu Jiang<sup>1</sup> · Nobuaki Takahashi<sup>1</sup> · Hideaki Kakeya<sup>1</sup> 

Received: 11 December 2023 / Revised: 8 February 2024 / Accepted: 4 March 2024 / Published online: 25 March 2024  
© The Author(s), under exclusive licence to the Japan Antibiotics Research Association 2024

## Abstract

The antimicrobial activity of tumescenamamide C against the scab-forming *S. scabiei* NBRC13768 was confirmed with a potent IC<sub>50</sub> value (1.5 µg/mL). Three tumescenamamide C-resistant *S. scabiei* strains were generated to compare their gene variants. All three resistant strains contained nonsynonymous variants in genes related to cellobiose/cellobiose transport system components; *cebF1*, *cebF2*, and *cebG2*, which are responsible for the production of the phytotoxin thaxtomin A. Decrease in thaxtomin A production and the virulence of the three resistant strains were revealed by the LC/MS analysis and necrosis assay, respectively. Although the nonsynonymous variants were insufficient for identifying the molecular target of tumescenamamide C, the cell wall component wall teichoic acid (WTA) was observed to bind significantly to tumescenamamide C. Moreover, changes in the WTA contents were detected in the tumescenamamide C-resistant strains. These results imply that tumescenamamide C targets the cell wall system to exert antimicrobial effects on *S. scabiei*.

## Introduction

*Streptomyces scabiei* (synonym: *Streptomyces scabies*) is a well-known pathogenic actinomycetes that is distributed in worldwide. This phytopathogen causes common scab disease, which results in scab-like lesions on the surface of potato tubers [1]. These lesions decrease the market value of potato crop, leading to significant economic losses [2]. Common scab lesions have also been detected on various agriculturally important root vegetables, including radish, carrot, beet, and turnip [3]. Thus, there is a critical need for effective methods for controlling *S. scabiei*.

Conventional methods for controlling *S. scabiei*, such as soil acidification, fumigation, pre-sowing seed tuber treatments, and crop rotations, are insufficient for preventing scab disease and environmentally burdensome [4]. A biocontrol-based strategy was recently revealed as a sustainable alternative to traditional disease control measure [5–7]. This strategy involves the use of plant-beneficial bacteria that produce various types of secondary metabolites. For example, *Bacillus* spp. producing cyclic lipopeptides (e.g., fengycin, iturin A, and surfactin) [6] and *Streptomyces melanosporofaciens* EF-76 producing the polyketide geldanamycin have inhibitory effects on scab-causing *Streptomyces* spp [8, 9].


Tumescenamamide C (Fig. 1b) is a cyclic lipodepsipeptide produced by *Streptomyces* sp. KUSC\_F05 strain. Its isolation, structure elucidation, and total synthesis have been accomplished in our laboratory [10, 11]. Interestingly, the antimicrobial activity of tumescenamamide C is considered to be specific to certain *Streptomyces* spp. including the producer *Streptomyces* sp. KUSC\_F05. According to a paper disc diffusion assay, the minimal amounts of tumescenamamide C required to inhibit growth were 3 µg/disc for *Streptomyces coelicolor* A3(2) and *Streptomyces lividans* TK23 and 30 µg/disc for *Streptomyces* sp. KUSC\_F05. In contrast, >100 µg/disc was required to inhibit the growth of the gram-positive

**Supplementary information** The online version contains supplementary material available at <https://doi.org/10.1038/s41429-024-00716-4>.

✉ Hideaki Kakeya  
scseigyohisyo@pharm.kyoto-u.ac.jp

<sup>1</sup> Department of System Chemotherapy and Molecular Sciences, Division of Medicinal Frontier Sciences, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto 606-8501, Japan

<sup>2</sup> Present address: Hachinohe College of Technology, Aomori 039-1192, Japan



**Fig. 1** Virulence assay of *S. scabiei* NBRC13768 and antimicrobial activity of tumescenamides C. **a** Assay of the virulence for *S. scabiei* NBRC13768. **(a)** *S. scabiei* NBRC13768 on MB medium containing 2% agar. **(b)–(e)** Results of the virulence bioassay involving sliced potato cubes (approximately 2 × 2 × 0.5 cm). Necrosis was detected around the site inoculated with *S. scabiei* NBRC13768 **(b)**, but not around the site incubated with MB medium **(c)** or the non-phytopathogenic *S. coelicolor*

A3(2) **(d)** and *S. lividans* TK23 **(e)**. **b** Chemical structure of tumescenamides C. **c** Antimicrobial activity of tumescenamides C against *S. scabiei* NBRC13768. Viability was calculated as the absorbance at 595 nm for each well containing tumescenamides C divided by the absorbance at 595 nm of the well lacking tumescenamides C. The estimated IC<sub>50</sub> value was 1.5 μg/mL.

bacteria *Staphylococcus aureus* NBRC13276 and *Bacillus subtilis* NBRC3134 as well as the gram-negative bacteria *Escherichia coli* NBRC3972 and *Pseudomonas aeruginosa* NBRC13275 [10]. The synthetic derivatives of tumescenamides C revealed the importance of the α,β-unsaturated moiety of Abu and the branched lipophilic side chain (Dmh) for the antimicrobial activity [11]. Because of the selective antimicrobial activity against *Streptomyces* spp., tumescenamides C and its producer *Streptomyces* sp. KUSC\_F05 may respectively be effective chemical and biological agents for controlling scab-forming *Streptomyces* spp., with no adverse effects on plant-beneficial microbes in the rhizosphere.

In this study, the antimicrobial activity of tumescenamides C against *S. scabiei* was evaluated. Moreover, we clarified the mode of action of tumescenamides C via comparative genetic and phenotypic analyses of the wild-type (WT) and tumescenamides C-resistant strains that we generated.

## Materials and methods

### General information

All commercially available reagents were purchased from Nacalai (Kyoto, Japan), Fujifilm-Wako (Osaka, Japan), Kanto Chemical (Tokyo, Japan), and Tokyo Kasei (Tokyo, Japan) unless described. Tumescenamides C was purified from *Streptomyces* sp. KUSC\_F05 strain according to our previous report [10]. *Streptomyces scabiei* NBRC13768 strain was distributed from National Institute of Technology and Evaluation (Tokyo, Japan). The strain was restored with Maltose-Bennett's (MB) medium (0.1% yeast extract, 0.1% beef extract, 0.2% N-Z-Amine A, 1% Maltose, pH 7.3) according to the distributor's instruction. For each experiment, a laboratory glycerol stock of the strain was spread on MB 2% agar medium and incubated at 27 °C for 3–7 days. Then, further experiments or inoculation in liquid MB medium were conducted appropriately under the conditions of 27 °C for 3–7 days with rotary agitation at 95 rpm/min. The laboratory

glycerol stocks were prepared as 4:1 ratio of the strain mycelia suspension with MB liquid medium and 80% glycerol in sterile water and stored at  $-80^{\circ}\text{C}$  until use. *S. coelicolor* A3(2) and *S. lividans* TK23 were distributed from Prof. H. Ikeda (Kitasato University) and maintained on ISP-2 medium (4% yeast extract, 10% malt extract, 4% glucose, pH7.0).

### Virulence assay for *Streptomyces* spp

To determine the phytopathogenic virulence of *S. scabiei* NBRC13768, potato tuber disc assay was conducted [12, 13]. Potato (Irish Cobbler potato; “Danshaku potato” in Japanese) purchased at supermarket was cut approximately  $2 \times 2 \times 0.5$  cm cubes after peeling. The cubes were put onto the petri dishes laid on moistened filter paper and wipes. Mycelia of *S. scabiei* on MB 2% agar broth maintained at  $27^{\circ}\text{C}$  was picked up with sterilized 200  $\mu\text{L}$  pipet tip and inoculated gentry onto potato cube described above. As control groups, MB medium and non-pathogenic *Streptomyces* spp.; *S. coelicolor* A3(2) and *S. lividans* TK23 were treated as the same procedure. Petri dishes were covered and placed at  $20^{\circ}\text{C}$  in the dark for 5 days. After 5 days-incubation, the inoculated potato was pictured.

### Antimicrobial activity of tumescenamamide C

A dilution series of tumescenamamide C in methanol (final conc. 0.001, 0.01, 0.1, 1, 10, 100, 500, and 1000  $\mu\text{g}/\text{mL}$ ) were dispensed in a 96 well plate (10  $\mu\text{L}/\text{well}$ ). The wells were fill up to 50  $\mu\text{L}/\text{well}$  with flesh MB liquid medium. *S. scabiei* NBRC13768 maintained in MB liquid medium was inoculated 150  $\mu\text{L}$  into the wells after unifying 0.04 in an absorbance at 595 nm. The plates were incubated at  $27^{\circ}\text{C}$  for 72 h without shaking. After 72 h, absorbance at 595 nm was measured using iMark (Bio-Rad Laboratories, Hercules, CA) ( $n = 3$ ). The  $\text{IC}_{50}$  values were calculated by GraphPad Prism (GraphPad Software, San Diego, CA).

### DiSC<sub>3</sub>(5) fluorescence assay

The membrane permeability of tumescenamamide C was tested using the voltage-sensitive dye DiSC<sub>3</sub>(5) (3,3'-dipropylthiadicarbocyanine iodide) [14]. *S. scabiei* NBRC13768 maintained in 5 mL MB liquid medium was centrifuged at  $1000 \times g$  for 10 min to recover the cell pellet. The pellet was washed with 5 mL PBS in twice and centrifuged again. After decantation, the pellet was suspended into 10 mL PBS containing 25 mM glucose to be 0.05 in an absorbance at 595 nm and incubated at  $28^{\circ}\text{C}$  for 15 min without shaking. After 15 min, the cell suspension was dispended into a 96 well shading plate at 180  $\mu\text{L}/\text{well}$ . Then, DiSC<sub>3</sub>(5) in DMSO solution (10  $\mu\text{L}/\text{well}$ ) was added to be a final concentration of 400 nM. The fluorescence intensity was

recorded every 1 min for 5 min to stabilize the fluorescence baseline. When the fluorescence baseline was stabilized, tumescenamamide C in methanol (10  $\mu\text{L}$ ) was quickly added to each well to be a final concentration of 2.5  $\mu\text{g}/\text{mL}$  and measured fluorescence every 30 s for 30 min. As controls, methanol, water, gramicidin, and penicillin (final conc. 10  $\mu\text{g}/\text{mL}$  in each compound) were tested. All fluorescence assay was in triplicate. The fluorescence plate reader utilized was Envision 2103-0020 (PerkinElmer, Waltham, MA) with excitation/emission 620/685 nm.

### Peptidoglycan (PG) binding assay

Peptidoglycan (PG) in *S. scabiei* NBRC13768 and its derivative strains conferring tumescenamamide C-resistance described below was isolated by the methods subjected to other gram-positive bacteria including *S. coelicolor* [15–17]. After random digestion of PG with mutanolysin [16], the mass spectra of PG fragments were recorded using a LC-ESI-IT-TOF-MS (Shimadzu, Kyoto, Japan) on the ESI-positive mode. YMC Pack Pro C18 ( $2.0 \times 150$  mm) (YMC, Kyoto, Japan) was chosen as the analytical column. The elution program was set to an isocratic of 2% B in A (0–5 min), a linear gradient of 5 to 15% B in A (5–30 min), a linear gradient of 15 to 100% B in A (30–40 min), and an isocratic of 100% B (40–55 min) at a flow rate of 0.2 mL/min. The solutions A and B are water and MeCN, respectively. Both A and B contain 0.1% HCOOH.

After verifying PG fragments with LC/MS analysis, binding ability of tumescenamamide C to peptidoglycans (PG) was surveyed according to the previous procedure [14]. Tumescenamamide C (15  $\mu\text{L}$  of 0.2 mg/mL in methanol) and PG without mutanolysin (75  $\mu\text{L}$  of 0.4 or 20 mg/mL in water) were filled up to 300  $\mu\text{L}$  with 20 mM phosphate buffer (pH 7.1) in a 1.5 mL tube and co-incubated at  $27^{\circ}\text{C}$  for 3 h with gentle shaking. The concentrations of PG in 0.4 and 20 mg/mL were set to make ratio of tumescenamamide C: PG as 1:10 and 1:500 (w/w), respectively. The co-incubated solution was centrifuged at  $11,000 \times g$  for 10 min. For quantification of non-binding free tumescenamamide C in the incubation mixture, the supernatant was analyzed by LC/MS/MS as selected reaction monitoring (SRM) mode using a LC-ESI-TQ-MS of LCMS8030plus (Shimadzu). YMC Pack Pro C18 ( $2.0 \times 150$  mm) was used as an analytical column. The elution program was set to an isocratic of 5% B in A (0–5 min), a linear gradient of 5 to 100% B in A (5–20 min), and an isocratic of 100% B (20–32 min) at a flow rate of 0.2 mL/min. The solution A and B are as described above. Three MS/MS fragment ions  $m/z$  86.15 (CE – 44 V), 337.15 (CE – 29 V), and 136.00 (CE – 40 V), which originated from the precursor ion of the  $[\text{M} + \text{H}]^+$  of tumescenamamide C ( $m/z$  700.43), were selected to verify the

probability of SRM monitoring. The SRM peak areas were calculated using LabSolution software (Shimadzu). As a positive control, binding ability of vancomycin was tested. The fragment ions were selected as  $m/z$  144.05 (CE – 19 V), 100.15 (CE – 43 V), and 83.10 (CE – 46 V) from  $[M + 2H]^{2+}$  of vancomycin ( $m/z$  725.40).

### Binding assay to wall teichoic acid (WTA)

The wall teichoic acid (WTA) in *S. scabiei* NBRC13768 and its derivative strains conferring tumescenamamide C-resistance described below was prepared by the previous procedure and analyzed by polyacrylamide gel electrophoresis (PAGE) [18].

As the lyophilized WTA extracts showed unfavorable solubility to adjust the concentrations for subsequent binding assay using LC/MS/MS analysis and none of the remarkable UV-Vis absorbance, contents of the extracts were alternatively measured at an absorbance at 260 nm. After checking the preparation of WTA by PAGE, WTA was diluted with 1 M Tris-HCl (pH 7.8) to be 0.5, 1.0, and 2.0 in an absorbance at 260 nm. Each diluted WTA (190  $\mu$ L) was mixed with 10  $\mu$ L of 0.2 mg/mL tumescenamamide C. The mixture was incubated for 3 h at 27 °C with gentle shaking. After centrifugation at 11,000  $\times g$  for 10 min, supernatant was recovered and subjected LC/MS/MS SRM mode for quantification of liberating tumescenamamide C. Analytical conditions were the same described in PG binding assay above.

### Generation of tumescenamamide C-resistant strains

The resistant strains for tumescenamamide C were generated from *S. scabiei* NBRC13768 by successive inoculation with the crescent of tumescenamamide C exposure concentration by referencing the previous report [19]. *S. scabiei* NBRC13768 maintained in MB liquid medium was diluted to be 0.02 in an absorbance at 595 nm. The diluted sample was inoculated to the flat-bottom 24 well plate (10  $\mu$ L/well) filled with 980  $\mu$ L/well of MB liquid medium containing the different concentrations of tumescenamamide C (final conc. 0.1, 0.2, 0.4, and 0.8  $\mu$ g/mL). The plate was incubated at 27 °C for 7 days with a rotary agitation (95 rpm/min). After 7 days, the strain in each well was inoculated into the new flat-bottom 24 well plate containing two-fold higher concentrations of tumescenamamide C in MB medium at the same incubating conditions. By repeating this inoculation procedure three times, five resistant strains (R1, R2, R3, R4, and R5) were obtained. No contamination of the other bacteria was confirmed by inoculating them on MB agar medium for the direct colony PCR to read 16S rRNA partial sequence [20]. The laboratory glycerol stocks of the resistant strains R1-R5 were prepared and stored at –80 °C for further

experiments. The IC<sub>50</sub> values of tumescenamamide C for R1-R5 were evaluated as described above.


### Genome mapping analysis

To compare the genetic backgrounds between wild type (WT; *S. scabiei* NBRC13768) and tumescenamamide C-resistant strains, three resistant strains of R1, R3, and R4 exhibiting weak or strong resistance to tumescenamamide C were selected and subjected to NGS-aided whole genome resequencing. The IC<sub>50</sub> values of tumescenamamide C for R1, R3, and R4 were 9.6, 19.3, and 24.1  $\mu$ g/mL, corresponding to 6.4, 12.9 and 16.1 times higher IC<sub>50</sub> values compared to that for the wild type (1.5  $\mu$ g/mL), respectively. The genomic DNAs were prepared from the wild type and three resistant strains (R1, R3, and R4) by the conventional phenol-chloroform extraction for sequencing analysis. The sequencing analysis was outsourced to Macrogen (Seoul, South Korea) with a paired ends of 151 read length of Illumina platform (Illumina, San Diego, CA). Reads were mapped to the reference complete genome sequence of *S. scabiei* 87-22 as a gene bank ID FN554889.1 [15]. The discovery of SNPs and indels was utilized SAMTools (<http://www.htslib.org>). Reads were assembled by Bio-Linux package (<http://environmentalomics.org/bio-linux/>) and genes containing SNP/indel were analyzed with IGV (<https://software.broadinstitute.org/software/igv/>). Gene annotations were searched by KEGG ([https://www.genome.jp/kegg/kegg\\_ja.html](https://www.genome.jp/kegg/kegg_ja.html)) and NCBI (<https://www.ncbi.nlm.nih.gov/>). Alignment figure was depicted using BioEdit [21].

### Evaluation of thaxtomin A production

Thaxtomin A production was analyzed in each strain. The ISP-4 2% agar medium containing 5% cellobiose was selected as the production medium of thaxtomin A [22]. The agar plate inoculated each strain was placed at 27 °C for 30 days to cover up aerial mycelia on gel surface sufficiently. Then, gels were crushed into 0.5–0.7 cm cubes and moved to 50 mL conical tubes for extraction with methanol. Extraction was conducted at 27 °C for 3 h with rotary shaking (95 rpm/min). After centrifugation at 3600  $\times g$  for 20 min, supernatant was filtered through gauze and concentrated *in vacuo*. After desalting by the SPE cartridge Strata C18-E (Phenomenex, Torrance, CA), organic component absorbed in the cartridge was eluted with methanol and dried up *in vacuo*. The dried eluent was resolved in methanol to be a concentration of 1 mg/mL for the LC/MS/MS analysis. Mass spectra were obtained using LC-ESI-TQ-MS of LCMS8030plus (Shimadzu) on the ESI positive and negative modes. Unison UK-C18 (2.0  $\times$  150 mm) (Imtakt, Kyoto, Japan) was used as the analytical column. The elution program was set to an isocratic of 5% B in A

**Fig. 2** Membrane permeability of tumescenamamide C. Membrane permeability was indicated by increases in the fluorescence intensity following the reaction involving the voltage-sensitive fluorescent dye DiSC<sub>3</sub>(5). Gramicidin, which has membrane disrupting activity, was selected as the positive control, penicillin, which targets cell wall components, was selected as the negative control



(0–5 min), a linear gradient of 5–100% B in A (5–20 min), an isocratic of 100% B (20–32 min) at a flow rate of 0.2 mL/min. The solution A and B are as described above. The <sup>1</sup>H NMR spectrum of the extract was recorded on a JEOL spectrometer at 500 MHz (Tokyo, Japan). The <sup>1</sup>H chemical shifts ( $\delta$ ) are shown relative to the residual solvent in CD<sub>3</sub>OD:  $\delta_{\text{H}}$  3.30. Chemical shifts ( $\delta$ ) are shown in parts per million (ppm).

### Cross-resistance assay

Cross-resistance for the other antibiotics were tested in three tumescenamamide C-resistant strains (R1, R3, and R4) by a paper disc diffusion assay. An optional series of antibiotics (novobiocin, puromycin, tetracycline, and penicillin) were separately loaded onto the paper discs ( $\phi$  8.0 mm, ADVANTEC Toyo Roshi, Tokyo, Japan) to be the concentrations at 0.5–100  $\mu\text{g}/\text{disc}$ . The discs containing each antibiotic was placed MB 2% agar medium after inoculation of each resistant strain. Incubation was conducted at 27 °C for 9 days. The compound amounts on disc were tested by preliminary experiments; novobiocin (0.5, 1, 10, and 100  $\mu\text{g}/\text{disc}$ ), puromycin (1, 10, and 100  $\mu\text{g}/\text{disc}$ ), tetracycline (1, 10, and 100  $\mu\text{g}/\text{disc}$ ), and penicillin (0.5, 1, 2.5, and 10  $\mu\text{g}/\text{disc}$ ). The inhibitory zones were measured every day for 9 days.

## Results


### Antimicrobial activity of tumescenamamide C against *Streptomyces scabiei*

We found that tumescenamamide C is a cyclic lipopeptide with selective antimicrobial activity against

*Streptomyces* spp [10, 11]. This *Streptomyces*-selective feature of tumescenamamide C could be a promising controlling agent against scab-forming *Streptomyces* spp. First, the virulence of the scab-forming *Streptomyces scabiei* NBRC13768 was assessed. The development of a necrotic lesion on a sliced potato cube verified the virulence of the strain that causes common scab (Fig. 1a). Then, the analysis of the antimicrobial activity of tumescenamamide C against *S. scabiei* NBRC13768 indicated the IC<sub>50</sub> value was 1.5  $\mu\text{g}/\text{mL}$  (Fig. 1c), which was consistent with the minimal amount required to inhibit the growth of other *Streptomyces* spp [10, 11].

### Evaluation of the membrane permeability and cell wall binding ability of tumescenamamide C

To clarify the mechanism underlying the antimicrobial activity of tumescenamamide C, its membrane permeability was measured using the voltage-sensitive fluorescent reagent DiSC<sub>3</sub>(5) [14]. The positive control (gramicidin) increased the intensity of the DiSC<sub>3</sub>(5) fluorescence, reflecting its membrane permeability. In contrast, the cell wall-targeting antibiotic penicillin and tumescenamamide C did not increase the fluorescence intensity, indicative of a lack of membrane permeability (Fig. 2). We subsequently examined the ability of tumescenamamide C to bind to cell wall components. First, peptidoglycan (PG), which is a major bacterial cell wall component, was isolated from *S. scabiei* NBRC13768 and compared with the structurally characterized PG of *S. coelicolor* [15]. The LC/MS analysis detected various ions with  $m/z$  values corresponding to *S. coelicolor* PG fragments [13768 (WT) in Table S1]. Notably, the detection of the monomers Tetra and Penta as well as the dimer TetraTetra suggests that the PG of *S. scabiei* NBRC13768 is structurally similar to that of *S. coelicolor*.



**Fig. 3** Binding of tumescenamide C to peptidoglycan and wall teichoic acid. **a** Assay of the binding to peptidoglycan (PG). The *x*-axis presents the PG:compound ratio (w/w). The *y*-axis presents the relative abundance, which was calculated using the following formula: (SRM peak area of the compound in PG:compound = 10:1 or 500:1)/(SRM peak area of PG:compound = 0:1). **b** Assay of the binding to wall


teichoic acid (WTA). The extract content was determined according to the absorbance at 260 nm (*x*-axis). The *y*-axis presents the relative abundance as in (a). Vancomycin was selected as the positive control. The asterisk indicates a significant difference ( $P < 0.01$ ) when compared with the relative abundance for 0:1 in (a) or 0 in (b)

Second, the potential binding between *S. scabiei* NBRC13768 PG and tumescenamide C was analyzed on the basis of the decreasing peak area of the tumescenamide C SRM ions. The peak area for positive control (vancomycin) decreased in a dose-dependent manner, which was in accordance with the fact this antibiotic targets PG. However, the lack of a dose-dependent decrease in the peak area implied tumescenamide C does not bind to PG (Fig. 3a).

We also examined the potential binding between tumescenamide C and wall teichoic acid (WTA), the characteristic cell wall component of gram-positive bacteria. After analyzing the WTA obtained from the strain by PAGE (Fig. S1) [18], the binding between tumescenamide C and WTA was evaluated. The vancomycin peak area decreased slightly in accordance with the change in the WTA content. In contrast, the tumescenamide C peak area decreased to 0.43 (relative abundance) during the incubation with the low absorbance WTA extracts (absorbance at 260 nm of 0.5) (Fig. 3b). Although a distinct dose-dependent decrease in the peak area was not observed for WTA, tumescenamide C may target this cell wall component and/or affect its biosynthesis.

### Generation of tumescenamide C-resistant strains and comparison of their genetic backgrounds

*S. scabiei* NBRC13768 strains resistant to tumescenamide C were generated, after which their genetic backgrounds were compared with that of the tumescenamide C-susceptible WT strain. Inoculations with increasing tumescenamide C concentration produced five resistant strains (R1, R2, R3, R4, and R5). The IC<sub>50</sub> values were >6.4-times higher for the




**Fig. 4** Antimicrobial activity of tumescenamide C against tumescenamide C-resistant strains. The IC<sub>50</sub> values were >6.4 times higher for the tumescenamide C-resistant strains than for the wild-type (WT) strain. The resistant strains that underwent the whole genome resequencing analysis are highlighted in orange (R1), green (R3), and blue (R4)

R1-R5 strains than the WT *S. scabiei* NBRC13768 (Fig. 4). More specifically, the IC<sub>50</sub> values of tumescenamide C for the R1, R3, and R4 strains were 9.6, 19.3, and 24.1 µg/mL, which were 6.4-, 12.9-, and 16.1-times higher than that of the WT control (1.5 µg/mL), respectively. To compare the genetic backgrounds, the WT control and the three resistant strains (R1, R3, and R4) exhibiting weak or strong resistance to tumescenamide C were subjected to NGS-aided whole genome resequencing. The assembled NGS sequences revealed the high GC contents, which were consisted with that of the complete *S. scabiei* 87-22 strain sequence genome (71.5%) [23]. The reads for WT, R1, R3, and R4 were mapped to the reference genome sequence (Table S2). Genes containing variants, such as SNPs and Indels, were extracted from the mapping data (Table S3). The annotation

**Fig. 5** The annotation process to extract the mutation genes in the tumescenamide C-resistant strains; R1, R3, and R4.

**a** Variants (SNPs and indels) in WT, R1, R3, and R4 were analyzed by mapping sequences on the complete *S. scabiei* 87-22 reference genome (FN554889.1, see Tables S2 and S3). By comparing each resistant strain vs WT, variants specific in the three resistant strains were picked up. In them, 162 genes with 409 variants were commonly observed in the three resistant strains, but not in WT. By BLAST searching of the 162 genes, a total of 19 genes were identified and listed in Table 1 as the variant genes common in the three resistant strains. Other genes were uncharacterized by the BLAST searching. **b** The variants specific genes in each resistant strain are listed in the supplementary Excel files entitled R1 vs WT, R3 vs WT, and R4 vs WT



process is depicted in Fig. 5. A total of 19 genes with variants affecting amino acid sequences in the three resistant strains (R1, R3, and R4), but not in WT, were identified (Table 1).

Eight of the 19 genes were predicted to encode enzymes that catalyze the degradation of alcohols, sugars, and proteins. The structure/motif associated with their variant positions was unidentified. Additionally, the motif of one gene encoding a stress response protein was uncharacterized. The structure/motif associated with the variant positions in the other 10 genes were predicted. Interestingly, of these 10 genes, the following four were related to sugar transport systems: *cebF* (SCAB\_2411), *cebG* (SCAB\_2401), *cellobiose transport system permease* (SCAB\_57741), and *sugar transport system permease* (SCAB\_28151). Moreover, SCAB\_2411, SCAB\_2401, and SCAB\_57741 encode components of the *cebEFG* cellobiose/cellotriose transport system [22, 24]. This system triggers the production of the phytotoxic compound thaxtomin A, which contributes to the necrosis observed in root vegetables infected with the common scab disease [7, 12, 24–26].

To date, two *cebEFG* systems have been reported [24]. The main cellobiose/cellotriose transporter genes (*cebEFG1*) in *S. scabiei* 87-22 are located in SCAB\_57721-

57761. As orthologous sequences, *cebEFG2* (SCAB\_2391-2431) encode proteins that are reportedly similar to *cebE1*, *cebF1*, and *cebG1* (46%, 58%, and 54% amino acid sequence identities, respectively). Experiments in which *cebE1* and *cebE2* are deleted revealed both genes encode proteins responsible for thaxtomin production. Among the phytopathogenic *Streptomyces* spp., only *S. scabiei* contains *cebEFG2*, which probably serves as a safeguard against the loss of the main transporter *cebEFG1* [24]. The genes *cebF* (SCAB\_2411), *cebG* (SCAB\_2401), and *cellobiose transport system permease* (SCAB\_57741) in Table 1 likely correspond to *cebF2*, *cebG2*, and *cebF1*, respectively (Table 1).

### Thaxtomin A production by the three tumescenamide C-resistant strains

Because the variants in the tumescenamide C-resistant strains were in genes encoding components of the cellobiose/cellotriose transport system, we analyzed the production of thaxtomin A by the three resistant strains. Thaxtomin A was undetectable in the cellobiose-containing liquid media (e.g., ISP-4 medium) inoculated with *S. scabiei* NBRC13768. Thus, extracts were prepared from solid ISP-4 medium containing 5% cellobiose and 2% agar [27].


**Table 1** Gene variants common to all three tumescenamamide C-resistant strains

Gene No.	Gene name	Function	Position in variant					Variant position
			87-22	WT	R1	R3	R4	
<b>SCAB_2401</b>	<b>carbohydrate ABC transporter permease</b>	<b>carbohydrate transport</b>	<b>A119</b>	<b>A119</b>	<b>S119</b>	<b>S119</b>	<b>S119</b>	Adjacent of F118, a residue constructing dimer interface
<b>SCAB_2411</b>	<b>sugar ABC transporter permease</b>	<b>carbohydrate transport</b>	<b>I184</b>	<b>I184</b>	<b>V184</b>	<b>V184</b>	<b>V184</b>	Three residues away of Q181, a residue constructing putative periplasmic-BP binding loops
SCAB_3831	GabD (aldehyde dehydrogenase family protein)	GABA shunt pathway	D245	D245	G245	G245	G245	D245, G247 ... catalytic residues with NAD(P) binding site D259, W273 ... within catalytic region
			D247	D247	D247	D247	D247	
			D259	D259	A259	A259	A259	
			W273	W273	R273	R273	R273	
SCAB_3851	<i>o</i> -L-fucosidase	N glycan degradation	C90	C90	W90	W90	W90	
SCAB_4031	HAMP domain-containing sensor histidine kinase	stress response, two component system	R170	R170	H170	H170	H170	Adjacent of L169, a residue constructing dimer interface
SCAB_4241	universal stress protein	stress response	H202	D202	N202	N202	N202	
SCAB_4611	LuxR family transcriptional regulator	transcriptional regulator	N878	N878	Y878	Y878	Y878	A residue for DNA binding site
SCAB_6541	alcohol dehydrogenase catalytic domain-containing protein	alcohol metabolism ?	V30	V30	L30	L30	L30	
			F34	F34	Y34	Y34	Y34	
			Q54	Q54	A54	A54	A54	
			N92	N92	D92	D92	D92	
			Q98	Q98	R98	R98	R98	
			R101	R101	H101	H101	H101	
			Q102	Q102	R102	R102	R102	
			I104	I104	V104	V104	V104	
			H106	H106	Q106	Q106	Q106	
			T78	N78	A78	A78	A78	
H104	Q104	D104	D104	D104	T78, H104 ... within NAD(P) binding site T119, T123, I128 ... within active site			
T119	T119	S119	S119	S119				
T123	T123	A123	A123	A123				
I128	I128	V128	V128	V128				
E45	E45	K45	K45	K45				
F106	F106	S106	S106	S106				
T140	T140	S140	S140	S140				
I171	I171	M171	M171	M171				
G172	S172	R172	R172	R172				
E219	E219	A219	A219	A219				
V225	A225	G225	G225	G225				
D42	D42	V42	V42	V42				
K145	M145	R145	R145	R145				
SCAB_12341	dioxigenase (catechol 1,2-dioxigenase)	benzoate degradation etc	E110	E110	K110	K110	K110	
SCAB_16371	DUF4357 domain-containing protein	restriction endonuclease	H435	H435	Y435	Y435	Y435	Adjacent of F436, a residue constructing walker B motif
SCAB_19651	putative quinone binding protein	unknown	L90	G90	A90	A90	A90	
			A91	deletion 91	G91	G91	G91	
SCAB_28151	carbohydrate ABC transporter permease	multiple carbohydrate transport	K162	K162	E162	E162	E162	Adjacent of successive 13 residues (E163-M175) constructing ABC-ATPase subunit interface
SCAB_36291	chaperonin GroEL	protein folding	Q154	K154	H154	H154	H154	Five residues away of F149, a residue constructing ATP/Mg binding site
SCAB_53281	putative peptidase	protein degradation	S237-D238	Insertion S237-P-D238	Insertion -D238	Insertion S237-WWP	Insertion S237-WWP	Insertion -D238
<b>SCAB_57741</b>	<b>putative cellobiose binding-protein-dependent transport system</b>	<b>cellobiose transport</b>	Y99	deletion Y99	deletion Y99	deletion Y99	deletion Y99	Y99, Q179 ... residues constructing dimer interface S203 ... a residue for ABC-ATPase subunit interface deletion S203 deletion S203 deletion S203 deletion S203 I152 ... adjacent of K151, putative periplasmic BP binding loops
			Q179	deletion	deletion	deletion	deletion	
			S203	deletion	deletion	deletion	deletion	
			I152	deletion	deletion	deletion	deletion	
				I152	F152	F152	F152	
SCAB_69911	transaldolase	pentose phosphate pathway etc	N234	Y234	H234	H234	H234	

The 19 listed genes contain variants that resulted in amino acid substitutions. Amino acid substitutions in important motifs (e.g., active site, NAD-binding site, and dimer-forming region) are indicated in red

The genes in bold and highlighted in blue encode components of the cellobiose/cellotriose transport system *cebEFG*


**Fig. 6** Extracted ion currents of thaxtomin A. Chromatograms were drawn as an extracted ion current (EIC) with  $m/z$  439.15 corresponding to the  $[M + H]^+$  of thaxtomin A. The differences in the thaxtomin A peak were confirmed via MS/MS fragmentation,  $^1\text{H}$  NMR analysis, and necrosis assay (see Fig. S2)



Hence, ensuring the turbidity of the samples with consistent was difficult. The weight of the gel extracts varied among the samples (1.3–1.6 mg for WT, 1.8–2.5 mg for R1, 1.4–1.6 mg for R3, and 1.0–1.3 mg for R4). All gel extracts (1 mg/mL in methanol) were included in the LC/MS analysis. Surprisingly, the thaxtomin A peaks were

substantially lower for R1, R3, and R4 than for WT (Fig. 6, Fig. S2). For R3 and R4, which were highly tolerant to tumescenamamide C ( $\text{IC}_{50}$  of 19.3 and 24.1  $\mu\text{g}/\text{mL}$  for R3 and R4, respectively; Fig. 4), the EIC peaks of thaxtomin A were nearly disappeared. Consistent with this observation, the virulence of R3 and R4 were also decreased (Fig. 7).





**Fig. 7** Necrosis assay for the tumescenamide C-resistant strains. Medium in control is the MB medium alone. *S. lividans* and *S. coelicolor* were placed as the paradigms of non-phytopathogenic *Streptomyces* spp. WT denotes *S. scabiei* NBRC13768. The R1, R3, and R4 are tumescenamide C-resistant strains derived from WT. The phytopathogenesis in the resistant strains was compared to WT

**Table 2** Cross-resistance of three tumescenamide C-resistant strains to selected antibiotics

Strain	Novobiocin (0.5 µg/disc)	Puromycin (100 µg/disc)	Tetracycline (10 µg/disc)	Penicillin (2.5 µg/disc)
WT	21.7	12.7	27.1	13.2
R1	28.3	14.1	27.7	25.2
R3	24.6	12.4	26.1	14.6
R4	25.2	8.7	29.4	9.5

Novobiocin, puromycin, tetracycline, and penicillin affect DNA synthesis (DNA gyrase), protein synthesis (ribosome), protein synthesis (30S ribosomal subunit), and cell wall synthesis (penicillin-binding protein), respectively. Values refer to the average diameters of the growth inhibition zones (mm)

### Cross-resistance assay and phenotypic evaluation of the three tumescenamide C-resistant strains

The WT, R1, R3, and R4 strains were compared in terms of their cross-resistance to the following antibiotics affecting different cellular processes: novobiocin (DNA synthesis), puromycin and tetracycline (protein synthesis), and penicillin (cell wall synthesis). For the novobiocin, puromycin, and tetracycline treatments, the growth inhibition zones were similar between the resistant strains and the WT strain, implying these antibiotics and tumescenamide C have different targets. However, the inhibitory effect of the penicillin treatment clearly differed between the WT and resistant strains. Furthermore, the growth inhibition zone diameters varied among the three resistant strains (Table 2). The R1 and R4 strains were respectively more and less susceptible to penicillin than the WT strain. In contrast, the R3 and WT strains were similarly susceptible to penicillin (Fig. S3). The changes in the susceptibility to penicillin among R1, R3, and R4 were suggestive of cell wall modifications. Accordingly, the strains were compared regarding their tolerance to temperature and osmotic stress. As expected, these three strains were differentially tolerant to

the two tested abiotic stress (Fig. S4). More specifically, R1 (highly susceptible to penicillin) was highly tolerant to the temperature and osmotic stresses, whereas R3 and R4 were relatively susceptible to these stresses.

### Wall teichoic acid (WTA) contents and cell wall-related gene variants in the three tumescenamide C-resistant strains

In the gram-positive methicillin-resistant *Staphylococcus aureus* (low GC content), changes in the susceptibility to penicillin and the tolerance to temperature and osmotic stresses are reportedly related to modifications to the cell wall component WTA [28]. In the current study, WTA and PG in the three tumescenamide C-resistant strains were analyzed. The detected PG-related ions were abundant in three resistant strains compared to those of WT strain (Table S1). In WTA, some remarkable differences were found in the migration of WTA in the PAGE gel (Fig. S5). The WTA bands for R3 and R4, which were respectively similarly susceptible and less susceptible to penicillin (compared with WT; Fig. S3), were less intensely stained and shifted upward compared with the WT WTA band, suggesting a high WTA content may enhance the susceptibility to tumescenamide C. The WTA band of R1 (highly susceptible to penicillin) migrated to a similar position as the WT WTA band, but it was more intensely stained (Fig. S5).

The differences in the susceptibility to the cell wall-targeting antibiotic penicillin, the susceptibility to temperature and osmotic stress, and the WTA band patterns among R1, R3, and R4 implied the resistance of these three strains to tumescenamide C was due to diverse modifications to the cell wall system. We re-analyzed the whole genome resequencing data to examine the gene variants in each resistant strain (WT vs R1, WT vs R3, and WT vs R4). The main gene variants in R1, R3, and R4 were detected in sequences encoding a response regulator transcription factor (18 nonsynonymous mutations), an ABC transporter substrate-binding protein (seven nonsynonymous mutations), and formyltetrahydrofolate deformylase (eight nonsynonymous mutations), respectively, indicating the tumescenamide C resistance of the three strains was not due to changes in the same functional protein or genetic locus (supplementary Excel files entitled R1 vs WT, R3 vs WT, and R4 vs WT). Next, genes encoding proteins contributing to cell wall synthesis were identified in the three tumescenamide C-resistant strains. After excluding the gene encoding unknown proteins, 12 of 70 in R1, 15 of 69 in R3, and 7 of 80 genes in R4 were related to cell wall synthesis (Fig. S6). Gene variants affecting PG synthesis were detected in all three strains, but variants were not detected in genes associated with WTA (Table S4).

## Discussion

The results of the present study indicate tumescenamamide C has potent antimicrobial effects on *S. scabiei*, the major phytopathogen causing common scab disease (Fig. 1c). To identify the gene variants associated with the resistance to tumescenamamide C, three resistant strains R1, R3, and R4 were selected for whole genome resequencing because they had relatively low and high  $IC_{50}$  values (i.e., 9.6, 19.3, and 24.1  $\mu\text{g}/\text{mL}$  for R1, R3, and R4, respectively) (Fig. 4). Intriguingly, 4 of 19 genes with variants in the three resistant strains encoded components of the carbohydrate transport system located in the periplasmic region (Table 1). Notably, SCAB\_2411, SCAB\_2401, and SCAB\_57741 encode cellobiose/cellotriose transport system components; *cebF2*, *cebG2*, and *cebF1*, respectively, which are responsible for the production of phytotoxic compound thaxtomin [3, 22, 24].

In accordance with the mutations in the genes encoding *cebs*, a substantial decrease in the thaxtomin A peak was observed in the R1, R3, and R4 (Fig. 6). Moreover, the phytopathogenic effects of these three resistant strains decreased (Fig. 7). These results suggested that resistance of tumescenamamide C might affect phytopathogenicity because of the associated decrease in the production of the major phytotoxin thaxtomin A. Although the nonsynonymous variants in *cebF2*, *cebG2*, and *cebF1* were located near or in the sequence encoding amino acid residues in important motifs, such as dimer interfaces and ATP-binding motifs (Table 1), most of the substituted amino acids were replaced by structurally similar amino acids (Table 1). The effects of these substitutions on the conformations of *cebF1*, *cebF2*, and *cebG2* remain unknown because of a lack of information regarding their crystallographic structures. These findings are quite interesting, but decreases in thaxtomin A production and phytopathogenicity are not directly correlated with the antibacterial activity of tumescenamamide C.

The other genes listed on Table 1 were encoding the transcriptional regulator LuxR family (SCAB\_4611), two-component systems (SCAB\_4031), and chaperon GroEL (SCAB\_36291), respectively. These proteins are known as attractive targets of antibiotics with a wide range of antibacterial spectra because of their conserved amino acid residual sequences and functional redundancy [29, 30]. However, these proteins might not be an important for the tumescenamamide C mode of action because of its characteristic antibacterial spectrum feature (e.g., 3–30  $\mu\text{g}/\text{disc}$  in *Streptomyces* spp. and >100  $\mu\text{g}/\text{disc}$  in *S. aureus*) [10]. Thus, further refinement for the molecular target of tumescenamamide C could not work well. To obtain some clues regarding the molecular target, cross-resistance assay involving known antibiotics was performed.

In the cross-resistance assay, the antibacterial effects of penicillin differed between the WT and resistant strains.

Notably, the susceptibility of the R1 strain to penicillin increased (Table 2, Fig. S3). Earlier research on methicillin-resistant *S. aureus* indicated that an increase in the susceptibility to penicillin is correlated with defective WTA biosynthesis [28, 31–33]. According to the in vitro binding assay, tumescenamamide C can bind to WTA, but not to PG (Fig. 3b). These observations suggest that the cell wall components could be a target of tumescenamamide C. The cell wall biosynthesis-related systems in the tumescenamamide C-resistant strains may have been altered, thereby limiting the adverse effects of tumescenamamide C. PG, which is the main cell wall component, was also analyzed for each strain. For PG, in addition to the variable fragment ions due to the random digestion with mutanolysin during the preparation of PG fragments for the mass spectroscopy, fragments of the same PG dimer and monomer structures were obtained for the WT and three resistant strains (Table S1). For WTA, the R1 strain (increased susceptibility to penicillin) had the highest WTA content among the examined strains (Fig. S5). This result was unexpected because the high susceptibility of methicillin-resistant *S. aureus* to penicillin is reportedly correlated with a decrease in the WTA content [28, 31–33]. The relationship between a high WTA content and enhanced susceptibility is currently unknown. However, high WTA contents might affect the overall cell wall structure or cell wall system, ultimately leading to increased susceptibility to penicillin. The other strains R3 and R4 slightly altered migration patterns on WTA-PAGE (Fig. S5), suggesting some changes of the cell wall system both in quality and quantity. The relatively high frequency in PG-fragment ions detected in three resistant strains compared to WT might be due to the diverse extraction efficiencies caused by the changes in cell wall intensity or system in each strain (Table S1). Taking these data and the result that tumescenamamide C showed the binding ability to WTA but not PG (Fig. 3), WTA is a crucial factor of antimicrobial activity by tumescenamamide C. The cell wall system (including WTA) is a vital, but structurally diverse, part of gram-positive bacteria [34, 35]. The structure of the outer part of the cell wall is recognized as an allergen by the mammalian immune-system [35]. It is reasonable to speculate that the *Streptomyces*-selective antibiotic activity of tumescenamamide C is related to the fact this compound targets the peripheral cell wall system. We previously determined that the  $\alpha,\beta$ -unsaturated moiety of Abu and branched lipophilic side chain (Dmh) are crucial for the antimicrobial activity of tumescenamamide C [11]. The lipophilic side chain might anchor the compound in the cell wall, whereas the  $\alpha,\beta$ -unsaturated moiety may act as the Michael acceptor [36] of cell wall component, including WTA.

Because we should consider the uncharacterized or overlooked genes as well as the mapping gaps, future studies will need to identify the molecular target of

tumescenamamide C. A recent transcriptomic analysis clarified the virulome response to cello-oligosaccharide elicitor in *S. scabiei* 87-22, suggesting the similar approach may be useful for further characterizing tumescenamamide C [25]. Moreover, molecular probe-based examinations of tumescenamamide C may be an alternative strategy.

In conclusion, the findings of this study elucidated the antimicrobial activity of tumescenamamide C against the scab-causing actinobacteria *S. scabiei*. Additionally, three tumescenamamide C-resistant strains generated in this study contained nonsynonymous mutations in the genes related to the cellobiose/cellotriose transport system (i.e., *cebEFG1* and *cebEFG2*). This transport system is crucial for the production of thaxtomin A, which promotes necrosis in root crops infected by the scab-causing phytopathogen *S. scabiei*. Comparing with the WT strain, the three tumescenamamide C-resistant strains with nonsynonymous variants in *cebEFG* genes produced less thaxtomin A and were less phytopathogenic. Although the molecular target of tumescenamamide C was not identified, our results suggest that cell wall components, such as WTA, may be target. More specifically, changes in the WTA contents were detected in the tumescenamamide C-resistant strains, while the binding between WTA and tumescenamamide C was confirmed. Research focused on identifying the molecular target and detailed mode of action of tumescenamamide C is currently underway in our laboratory.

## Data availability

Data sets generated for this study are included in this article or supporting information; further information can be directed to the corresponding author (H.K.).

**Acknowledgements** This work was supported by a Grant-in Aid for Scientific Research on Innovative Areas (No. 17H06401 to HK) and for the Transformative Research Area (A) (No. 23H04882 to HK) from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT), Japan, and the Research Support Project for Life Science and Drug Discovery [Basis for Supporting Innovative Drug Discovery and Life Science Research (BINDS)] from the Japan Agency for Medical Research and Development (AMED), Japan. This work was also inspired by the international and interdisciplinary environments of JSPS Asian CORE program, “Asian Chemical Biology Initiative”.

## Compliance with ethical standards

**Conflict of interest** The authors declare no competing interests.

## References

- Li Y, Liu J, Díaz-Cruz G, Cheng Z, Bignell DRD. Virulence mechanisms of plant-pathogenic *Streptomyces* species: an updated review. *Microbiol*. 2019;165:1025–40.
- Loria R, Kers J, Joshi M. Evolution of plant pathogenicity in *Streptomyces*. *Annu Rev Phytopathol*. 2006;44:469–87.
- Liu J, Nothias L-F, Dorrestein PC, Tahlan K, Bignell DRD. Genomic and metabolomic analysis of the potato common scab pathogen *Streptomyces scabiei*. *ACS Omega*. 2021;6:11474–87.
- Dees M, Wanner L. In search of better management of potato common scab. *Potato Res*. 2012;55:249–68.
- Arseneault T, Goyer C, Filion M. Biocontrol of potato common scab is associated with high *Pseudomonas fluorescens* LBUM223 populations and phenazine-1-carboxylic acid biosynthetic transcript accumulation in the potato geocaulosphere. *Phytopathol*. 2016;106:963–70.
- Lin C, Tsai C-H, Chen P-Y, Wu C-Y, Chang Y-L, Yang Y-L. Biological control of potato common scab by *Bacillus amyloliquefaciens* Ba01. *PLoS One*. 2018;13:e0196520
- Biessy A, Filion M. Biological control of potato common scab by plant-beneficial bacteria. *Biol Control*. 2022;165:104808–21.
- Toussaint V, Valois D, Dodier M, Faucher E, Déry C, Brzezinski R. Characterization of actinomycetes antagonistic to *Phytophthora fragariae* var. *rubi*, the causal agent of raspberry root rot. *Phytoprotection*. 1997;78:43–51.
- Beauséjour J, Clermont N, Beaulieu C. Effect of *Streptomyces melanosporofaciens* strain EF-76 and of chitosan on common scab of potato. *Plant Soil*. 2003;256:463–8.
- Kishimoto S, Tsunematsu Y, Nishimura S, Hayashi Y, Hattori A, Kakeya H. An antimicrobial cyclic lipodepsipeptide from *Streptomyces* sp. *Tetrahedron*. 2012;68:5572–8.
- Takahashi N, Kaneko K, Kakeya H. Total synthesis and antimicrobial activity of tumescenamamide C and its derivatives. *J Org Chem*. 2020;85:4530–5.
- Loria R. Differential production of thaxtomins by pathogenic *Streptomyces* species in vitro. *Phytopathology*. 1995;85:537–41.
- Bignell DRD, Francis IM, Fyans JK, Loria R. Thaxtomin A production and virulence are controlled by several *bld* gene global regulators in *Streptomyces scabies*. *Mol Plant Microbe Interact*. 2014;27:875–85.
- Culp EJ, Waglechner N, Wang W, Fiebig-Comyn AA, Hsu Y-P, Koteva K, et al. Evolution-guided discovery of antibiotics that inhibit peptidoglycan remodelling. *Nature*. 2020;578:582–7.
- van der Aart LT, Spijksma GK, Harms A, Vollmer W, Hanke-meier T, van Wezel GP. High-resolution analysis of the peptidoglycan composition in *Streptomyces coelicolor*. *J Bacteriol*. 2018;200:e00290–18.
- Schaub RE, Dillard JP. Digestion of peptidoglycan and analysis of soluble fragments. *Bio-Protoc*. 2017;7:2438.
- Kühner D, Stahl M, Demircioglu DD, Bertsche U. From cells to mucopeptide structures in 24 h: peptidoglycan mapping by UPLC-MS. *Sci Rep*. 2014;4:7494.
- Kho K, Meredith TC. Extraction and Analysis of Bacterial Teichoic Acids. *Bio-Protoc*. 2018;8:e3078.
- Imai Y, Meyer KJ, Iinishi A, Favre-Godal Q, Green R, Manuse S, et al. A new antibiotic selectively kills gram-negative pathogens. *Nature*. 2019;576:459–64.
- Bowden G, Johnson J, Schachte C. The predominant actinomycetes spp. isolated from infected dentin of active root caries lesions. *J Dent Res*. 1993;72:1171–9.
- Hall TA. BioEdit: a user-friendly biological sequence alignment editor and analysis 33 program for Windows 95/98/NT. *Nucleic Acids Symp Ser*. 1999;41:95–8.
- Jourdan S, Francis IM, Kim MJ, Salazar JJC, Planckaert S, Frère J-M, et al. The CebE/MsiK transporter is a doorway to the cellobiosaccharide-mediated induction of *Streptomyces scabies* pathogenicity. *Sci Rep*. 2016;6:27144
- Bignell DR, Seipke RF, Huguet-Tapia JC, Chambers AH, Parry RJ, Loria R. *Streptomyces scabies* 87-22 contains a coronafacic acid-like biosynthetic cluster that contributes to plant-microbe interactions. *Mol Plant Microbe Interact*. 2010;23:161–75.
- Francis IM, Bergin D, Deflandre B, Gupta S, Salazar JJC, Villagrana R, et al. Role of alternative elicitor transporters in the onset

- of plant host colonization by *Streptomyces scabiei* 87–22. *Biology*. 2023;12:234–52.
25. Deflandre B, Stulanovic N, Planckaert S, Anderssen S, Bonometti B, Karim L. et al. The virulome of *Streptomyces scabiei* in response to cello-oligosaccharide elicitors. *Microb Genom*.2022;8:000760
  26. Kinkel LL, Bowers JH, Shimizu K, Neeno-Eckwall EC, Schottel JL. Quantitative relationships among thaxtomin A production, potato scab severity, and fatty acid composition in *Streptomyces*. *Can J Microbiol*. 1998;44:768–76.
  27. Jourdan S, Francis IM, Deflandre B, Tenconi E, Riley J, Planckaert S. et al. Contribution of the  $\beta$ -glucosidase BglC to the onset of the pathogenic lifestyle of *Streptomyces scabies*. *Mol Plant Pathol*. 2018;19:1480–90.
  28. Wang H, Gill CJ, Lee SH, Mann P, Zuck P, Meredith TC. et al. Discovery of wall teichoic acid inhibitors as potential anti-MRSA  $\beta$ -lactam combination agents. *Chem Biol*. 2013;20:272–84.
  29. Bem AE, Velikova N, Pellicer MT, van Baarlen P, Marina A, Wells JM. Bacterial histidine kinases as novel antibacterial drug targets. *ACS Chem Biol*. 2015;10:213–24.
  30. Kunkle T, Abdeen S, Salim N, Ray A-M, Stevens M, Ambrose AJ. et al. Hydroxybiphenylamide GroEL/ES inhibitors are potent antibacterials against planktonic and biofilm forms of *Staphylococcus aureus*. *J Med Chem*.2018;61:10651–64.
  31. Swoboda JG, Meredith TC, Campbell J, Brown S, Suzuki T, Bollenbach T. et al. Discovery of a small molecule that blocks wall teichoic acid biosynthesis in *Staphylococcus aureus*. *ACS Chem Biol*.2009;4:875–83.
  32. Campbell J, Singh AK, Santa Maria JP,Jr., Kim Y, Brown S, Swoboda JG. et al. Synthetic lethal compound combinations reveal a fundamental connection between wall teichoic acid and peptidoglycan biosyntheses in *Staphylococcus aureus*. *ACS Chem Biol*.2011;6:106–16.
  33. Lee SH, Wang H, Labroli M, Koseoglu S, Zuck P, Mayhood T. et al. TarO-specific inhibitors of wall teichoic acid biosynthesis restore  $\beta$ -lactam efficacy against methicillin-resistant staphylococci. *Sci Transl Med*.2016;8:329ra32
  34. Naumova IB, Shashkov AS, Tul'skaya EM, Streshinskaya GM, Kozlova YI, Potekhina NV. et al. Cell wall teichoic acids: structural diversity, species specificity in the genus *Nocardiopsis*, and chemotaxonomic perspective. *FEMS Microbiol Rev*.2001;25:269–83.
  35. Brown S, Santa Maria JP Jr, Walker S. Wall teichoic acids of gram-positive bacteria. *Annu Rev Microbiol*. 2013;67:313–36.
  36. Takenaka K, Kaneko K, Takahashi N, Nishimura S, Kakeya H. Retro-aza-Michael reaction of an *o*-aminophenol adduct in protic solvents inspired by natural products. *Bioorg Med Chem*. 2021;35:116059–116059.

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.